Sickle Cell Patient and Parent Satisfaction with Pain Management in the Emergency Department by Smith-Packard, Bethanny
  
SICKLE CELL PATIENT AND PARENT SATISFACTION WITH PAIN 
MANAGEMENT IN THE EMERGENCY DEPARTMENT 
 
 
 
 
 
 
 
 
by 
Bethanny Smith-Packard 
B.S. Bio-Molecular Science and Psychology, Clarkson University, 2007 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
The Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Master of Science 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2009 
 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
 
 
 
 
 
 
This thesis was presented 
 
by 
 
 
Bethanny Smith-Packard 
 
 
 
 
It was defended on 
March 24, 2009 
and approved by 
Elizabeth Gettig, M.S., CGC 
Associate Professor of Human Genetics 
Co-Director, Genetic Counseling Program 
Graduate School of Public Health, University of Pittsburgh 
 
Committee Members: 
Lakshmanan Krishnamurti, MD 
Associate Professor of Pediatric Medicine, Department of Pediatric Medicine 
Program Director; Hemoglobinopathy Program 
Children’s Hospital of Pittsburgh; University of Pittsburgh Medical Center 
 
Sonia Singh MD, MPH, MBA 
Assistant Professor of Pediatrics 
Medical Director, Fast Track 
Division of Pediatric Emergency Medicine Children's Hospital of Pittsburgh 
 ii 
Copyright © by Bethanny Smith-Packard 
2009 
 iii 
SICKLE CELL PATIENT AND PARENT SATISFACTION WITH PAIN 
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University of Pittsburgh, 2009
 
Sickle cell disease (SCD) is associated with significant morbidity, mortality and impaired quality 
of life. Vaso-occlusive pain crises are the hallmark of sickle cell disease and require frequent 
visits to the emergency room and admissions to the hospital. Even though national guidelines are 
available that address the ethical issues of pain management, patients with SCD often receive 
suboptimal pain control, especially during acute painful episodes. This project planned to 
determine some methods of improving patient care and satisfaction of pain management in hopes 
of being able to translate these methods to other health care systems.  
At the Children’s Hospital of Pittsburgh (CHP) individualized pain plans, which include 
lists of each patient’s most recent pain medications, have been in place since 2002. Retrospective 
data was analyzed to determine whether admission rates have decreased since this time due to 
improved care and treatment of patients with SCD. Additionally, patient and parent satisfaction 
with current pain management was evaluated by the use of surveys, with questions regarding 
overall perceptions of treatment and care. We had also proposed to implement a quality 
improvement program in the ED to further improve care of patients with sickle cell disease 
presenting with vaso-occlusive pain crises and then reassess patient and parent satisfaction. 
However, time restraints did not allow a quality improvement program to be implemented at this 
time.  
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This study found that admission rates since 2002 had decreased at CHP, since the time 
that individualized pain plans were designed and put into practice. Baseline measurements of 
patient and parent satisfaction found that, overall, participants were satisfied with the care and 
treatment of pain they received in the ED. Future studies should involve developing further 
methods of improving patient satisfaction with pain management; a possible avenue to pursue 
may be working on decreasing wait times in the ED.  
The public health significance of this research is that increasing satisfaction by improved 
care, treatment, and pain management may lead to improved quality of life for patients with 
SCD; additionally, similar steps to be taken in other hospitals to increase the level of pain 
management that sickle cell patients receive.   
 v 
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1.0  INTRODUCTION 
It has been estimated that approximately 70,000 Americans have sickle cell disease (Givens et 
al., 2007). Sickle cell disease (SCD) is a hemolytic anemia associated with significant morbidity, 
mortality and impaired quality of life. In patients with SCD, polymerization of red blood cells 
results in a rigid, sickle-shaped cell that can cause various problems throughout the body. Vaso-
occlusive pain crises are the hallmark of sickle cell disease and require frequent visits to the 
emergency room and admissions to the hospital. Studies have found that prevention of prolonged 
pain crises may help to reduce long-term health consequences (Jacob & Mueller, 2008).  
Treatment that is individualized for each patient, as well as increased physician knowledge 
regarding all aspects of SCD, has been found to lead to more effective pain management for 
patients with SCD (Ballas, 2005). Despite the availability of national guidelines that address the 
ethical issues of pain management (Joint Commission for the Accreditation of Healthcare 
Organizations (JCAHO) and the American Pain Society), patients with SCD often receive 
suboptimal pain control, especially during acute painful episodes (Jacob et al., 2003).  
A large number of physicians and health care professionals are not familiar with SCD and 
the characteristic pain episodes. This may lead to sickle cell patients being perceived as drug 
seekers or abusers by health care professionals not familiar to their needs for pain relief (Aisiku 
et al., 2007).  Limited knowledge or experience with SCD may lead to mistrust of the patient by 
the physician which may actually lead to over-control of pain management. In turn, this can 
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result in the patient having decreased knowledge and independence, and increased anxiety, in 
regards to the treatment of his/her pain (Maxwell et al., 1999). Overall, this may lead to 
suboptimal care of these patients and decreased patient satisfaction with pain management, 
especially in the emergency department.  If ED staff is trained specifically about sickle cell 
disease, pain management and treatment may be improved in patients leading to increased 
patient satisfaction.  
At the Children’s Hospital of Pittsburgh of UPMC, individualized pain plans for each 
sickle cell patient were implemented in the ED from 2002 to 2003. These plans include 
medication plans for the patient when seen in the ED, if they are admitted, and their home 
medication list. Whenever the patient is seen and changes to their dose are made, this 
information is updated, so that the ED always has the most current pain management information 
for each patient. Analysis of retrospective data from 2002 to present will be used to determine 
how these individualized pain plans have affected variables of patient care, such as rates of 
admissions and readmissions. These numbers will be compared to data from other hospitals 
across the country with similar pediatric sickle cell programs; this data was collected through the 
Pediatric Health Information System (PHIS).  
This study will gauge patient and parent satisfaction with pain management in the ED 
following the implementation of individualized pain management and more knowledgeable staff. 
Patient and parent satisfaction will be measured by use of survey regarding overall care, 
treatment, and pain management. This survey will be administered to patients (ages 5-21) and 
their parents who were seen at a hospital emergency department upon completion of their care. It 
is believed that patient and parent satisfaction will be high due to individualized pain plans and 
increased knowledge and understanding of SCD.  
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The public health significance of this research is that by determining sickle cell patient 
and parent satisfaction after the implementation of personalized pain plans in the emergency 
department similar steps may be taken in other hospitals or in ambulatory care to increase the 
level of pain management that sickle cell patients receive.  Additionally, increasing satisfaction 
by improved care, treatment, and pain management may lead to improved quality of life for 
patients with SCD.  
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2.0   SPECIFIC AIMS 
2.1 SPECIFIC AIM I 
Evaluate and compare retrospective data about sickle cell patients from Children’s Hospital of 
Pittsburgh and Child Health Corporation of America (CHCA) hospitals. 
 
Rationale: In the past few years, advances have been made in the care and treatment of patients 
with sickle cell disease. Treatment of patients has improved as understanding of sickle cell 
disease has increased. In patients with sickle cell disease, when pain is managed early and 
aggressively outcomes include better control of pain, reduced suffering, and decreased 
hospitalizations. Previous studies have found that improved treatment of pain results in 
decreased hospital admissions. Thus, rates of hospital admissions will be used as a surrogate 
marker to measure the quality of pain management.  Retrospective data from CHP and various 
hospitals with similar pediatric sickle cell populations and programs will be evaluated from 2002 
to the present.  
 
Hypothesis: Individualized pain management plans implemented at CHP from 2002-2003 have 
improved the quality of pain management for patients with SCD by reducing rates of admissions.  
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 2.2 SPECIFIC AIM II 
Evaluate the current levels of patient and parent satisfaction with vaso-occlusive pain crisis 
management in the Emergency Department.  
 
Rationale:  Measuring current satisfaction levels will help determine a baseline level of patient 
and parent satisfaction.  
 
Hypothesis: Improved quality of care for patients with SCD and their parents will lead to high 
levels of satisfaction with pain management, care, and treatment because pain levels are quickly 
and effectively reduced.  
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3.0  BACKGROUND AND SIGNIFICANCE 
3.1 SICKLE CELL DISEASE 
3.1.1 Molecular genetics of sickle cell disease 
Sickle cell disease (SCD) is any inherited condition that causes a change in the structure or 
quantity of the hemoglobin molecule. Hemoglobin is a tetramer molecule comprised of two α-
globin subunits and two β-globin subunits. Mutations in the HBB gene can cause abnormal 
structure or folding of the β-globin subunit, or β-chain. In classic SCD, a point mutation at the 
second nucleotide of the sixth codon of the β-chain will substitute a glutamic acid with valine. 
The abnormal structural variant of hemoglobin that is produced by this mutation is referred to as 
hemoglobin S (HbS). If an individual is homozygous for this point mutation, they have sickle 
cell anemia (HbSS).  In compound heterozygotes, other mutations can occur in the β-globin 
genes that will cause an individual to be affected with SCD. Compound heterozygotes with 
hemoglobin S and hemoglobin C or β-thalessemia will also have SCD (HbSβ+ and HbSβ0) 
(Wilson et al., 2003).  While there is a lot of variability in how an individual will present with 
SCD, generally those with HbSS or HbSβ0-thalessemia will be more severe (Wilson et al., 
2003).   Sickle cell disease is inherited in an autosomal recessive manner.  
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3.1.2 Incidence of Sickle Cell Disease 
It has been estimated that approximately 70,000 Americans have sickle cell disease (SCD) 
(Givens et al., 2007).  This disease most frequently affects individuals of African and 
Mediterranean descent; however, it can also affect individuals of Middle Eastern, Arabian, 
Indian, Caribbean, and South and Central American descent (Wethers, 2000a; Wilson et al., 
2003).  In African-Americans, the prevalence of sickle cell trait is about 8-10%; about 2000 
babies with sickle cell disease are born each year in the United States. This means that about one 
in every 250-600 African-Americans born in the United States has sickle cell disease (Shafer et 
al., 1996). 
 A higher incidence of the sickle cell gene has been found in individuals with descent 
from regions where malaria is common (figures 1 and 2). This is thought to be due to a 
heterozygote advantage, where people with sickle cell trait have an increased resistance to fatal 
malaria (Aidoo et al., 2002). 
 
Figure 1: Areas with malaria 
http://anthro.palomar.edu/synthetic/synth_4.htm 
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 Figure 2: Areas with increased incidence of sickle cell trait 
http://anthro.palomar.edu/synthetic/synth_4.htm 
3.1.3 Natural History and Clinical Features of Sickle Cell Disease  
In the human body, the function of hemoglobin is to transport molecules of oxygen from the 
lungs to the rest of the body. This function is hindered in individuals with SCD due to hemolysis 
and episodic vascular occlusion. Vaso-occlusion is the cause of the acute pain crises 
characteristic of SCD; it is caused by the polymerization, and subsequent aggregation, of the 
HbS molecules during deoxygenation. During this polymerization, red blood cells become sickle 
shaped, rigid, and less flexible. The damaged red blood cells, endothelium, and platelets increase 
the expression of adhesion molecules and may play a role in the initiation of vaso-occlusion. 
Vaso-occlusion can cause tissue ischemia which may result in acute and chronic organ damage 
or dysfunction. Hemolysis may reduce red blood cell survival from about 120 days to 20 days 
resulting in chronic anemia, jaundice, predisposition to aplastic crisis, and delayed growth and 
development (Wilson et al., 2003).  
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 Figure 3: Process of vaso-occlusion 
(Stuart & Nagel, 2004) 
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Often the first clinical manifestation of SCD is dactylitis, or hand-foot syndrome, seen in 
children under the age of three.  This is a painful swelling of the hands and feet due to vaso-
occlusion and may be a predictor of a more severe course of disease in a child. Vascular 
occlusion may occur anywhere in the body and therefore pain may be felt anywhere in the body; 
however, the most common areas where pain is experienced are the chest, back, abdomen, and 
limbs (Stuart & Nagel, 2004). Vascular occlusion can lead to tissue infarction, and possibly, a 
state of inflammation (suggested by in vivo studies of transgenic mice) that leads to the sensation 
of pain. Currently, the exact pathophysiologic sequence of events that leads to the perception of 
pain is unknown, but is believed to be complex, hence the considerable variability of pain 
experiences in this disease. Pain may be acute or chronic, unilateral or bilateral, visceral or 
somatic, localized or diffuse, and mild, moderate, or severe (Ballas, 2005). Caregivers should 
learn how to recognize and manage a pain crisis. In the case of mild to moderate pain, oral 
analgesics can frequently be used. If pain is not alleviated by this method, patients should be 
triaged and given IV narcotics if necessary (Wilson et al., 2003).  
Children with SCD should be started on prophylactic penicillin by two months of age due 
to their increased risk for infections (Wethers, 2000a; Wilson et al., 2003). The development of 
splenic dysfunction at a young age increases the risk for children to experience infections from 
encapsulated bacteria, specifically Streptococcus pneumoniae, leading to sepsis. Penicillin 
should be given daily until at least the age of five. If the child has a history of pneumococcal 
infection, penicillin should be continued throughout his/her life (Wilson et al., 2003). Along with 
prophylactic antibiotics, children should receive all routine immunizations, as well as the 
pneumococcal-conjugated vaccine (PCV 7, Prevnar) and the pneumococcal polysaccharide 
vaccine (PPV23), the yearly influenza vaccine, and a semi-yearly meningococcal vaccine 
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(Wethers, 2000a; Wilson et al., 2003). If a child with SCD develops a fever over 38.5° Celsius or 
other signs of infection, he/she should be evaluated immediately because of the risk for sepsis 
due to splenic dysfunction. Evaluation should include a complete blood count and culture, a 
chest x-ray, and a physical exam. IV antibiotics should be started as soon as possible, as well 
(Wilson et al., 2003).  
Besides pain crisis and infection, acute chest syndrome (ACS) is another common cause 
of hospital admission in patients with SCD.  ACS is characterized by identifying new pulmonary 
infiltrate on a chest radiograph as well as the presence of other symptoms such as fever, cough, 
chest pain, shortness of breath, and wheezing. ACS may develop after an episode of vaso-
occlusive pain or in conjunction with an acute infection (most often a pulmonary infection, 
infarct, or fat embolism) (Wethers, 2000b; Wilson et al, 2003). Treatment of ACS should be 
aggressive as pulmonary failure and death may occur. Treatment involves the use of oxygen, 
analgesics, antibiotics, and exchange transfusion while being closely observed in a hospital 
(Wilson et al., 2003).  
The risk for stroke in patients with SCD is significant and occurs due to the 
polymerization and accumulation of HbS in the vasculature of the brain. The incidence of stroke 
is highest between ages 4-6; about 10% of patients with SCD have strokes (Wethers, 2000b). 
Children should be evaluated if they have any neurological symptoms other than a headache, a 
stroke may present as a severe headache, stupor, hemiparesis, dysphasia, cranial nerve palsy, or 
coma. Evaluations for stoke should include magnetic resonance imaging (MRI) or computed 
tomography (CT) without contract, as well as a complete blood count (Wilson et al, 2003).  
Transcranial Doppler (TCD) ultrasonography may be done annually for HbSS patients beginning 
at two years of age. Blood flow velocity over 200 cm per second on TCD indicates an increased 
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risk for stroke (Wong & Powars, 2005). Patients who have had a stroke or are at risk based on 
TCD should undergo routine exchange transfusion (Wilson et al, 2003). 
Pulmonary hypertension is one of the most serious and frequent complications in 
individuals with SCD. It is approximated that about 32% of adults with SCD will develop 
pulmonary hypertension (Castro & Gladwin, 2005). The pathophysiology of pulmonary 
hypertension is still unknown, although it is most likely multifactorial. The polymerization of 
HbS leads to fragility of red blood cells and their subsequent breakdown, or hemolysis. 
Hemolysis interferes with how nitric oxide is synthesized and utilized, and thus produces 
dysfunction in vasoconstriction.  Screening for pulmonary hypertension is done by transthoracic 
Doppler echocardiogram and should be performed in all adults with SCD. If left untreated, the 
median survival time for individuals with pulmonary hypertension is 2.8 years (Castro & 
Gladwin, 2005).  
Splenic sequestration is a complication of SCD recognized by an enlarging spleen, a 
decrease in hemoglobin levels, and a rise in reticulocyte levels. This typically occurs before the 
age of five and is caused by increased infections and immune dysfunction. Treatment for splenic 
sequestration is red blood cell transfusion. Prior to age two, chronic transfusion can be performed 
in children with severe or recurrent splenic sequestration; splenectomy should be considered for 
patients over two years of age if hypersplenism is chronic (Stuart & Nagel, 2004; Wethers, 
2000b; Wilson et al., 2003).  
Aplastic crisis is another complication of SCD where there is a temporary cessation of the 
production of red blood cells; this can lead to severe anemia. Aplastic crisis is typically triggered 
by an infection; most cases are caused by the human parvovirus B19. Many patients will recover 
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spontaneously, but red blood cell transfusions may be required if there is no evidence of recovery 
(Stuart & Nagel, 2004; Wethers, 2000b; Wilson et al., 2003). 
Priapism is a painful, prolonged, and unwanted erection that is a common complication 
of SCD in males with almost 90% experiencing priapism by age 20.  When it lasts less than 3 
hours and resolved spontaneously, it is classified as a stuttering form. If it lasts over three hours, 
it is classified as a severe form and requires medical attention due to increased risks for fibrosis 
and impotence. Treatment of priapism should include IV hydration, analgesics, and exchange 
transfusion or penile aspiration of blood in the case of persistent or recurrent priapism (Stuart & 
Nagel, 2004; Wilson et al., 2003). 
There are other health complications in patients with SCD that may be a result of chronic 
hemolysis. Gallstones may be caused by chronic hemolysis, with about 30% of patients with 
SCD developing them by age 18. These can be treated by cholecystectomy (Wethers, 2000b; 
Wilson et al., 2003). Liver dysfunction may occur due to vascular occlusion or chronic hepatitis 
and can be treated by exchange transfusion (Ballas, 2005).  
In patients with SCD, there can be many structural and functional abnormalities of the 
kidneys. The kidney is especially sensitive to vaso-occlusion due to deoxygenation since the 
environment in the kidney is characterized by acidosis, hypertonicity, and hypoxia. All of these 
factors are involved in promoting HbS polymerization and may cause dehydration, which also 
leads to HbS polymerization. Problems with the kidneys in SCD patients may result in 
proteinuria and hematuria, which can be life threatening (Ataga & Orringer, 2000; Wethers, 
2000b).  
Leg ulcers can also occur in patients with SCD. The exact etiology of the leg ulcers is 
unclear; however, they occur in about 10-20% of patients, often between the ages of 10-25. 
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There is a higher likelihood of leg ulcers in males, as well (Serjeant et al., 2005).  Treatment 
includes using wet and dry dressings soaked in saline and many ulcers heal within a few months; 
if the ulcers persist beyond six months, skin grafting or blood transfusion may be required. 
Pressure stockings may help to prevent the formation of leg ulcers since they may recur 
following minimal trauma (Ballas, 2005).  
In addition to the physical manifestations of SCD, there are also psychological factors to 
consider. Individuals with SCD experience chronic pain, which is defined as pain that persists for 
three months or more. A key feature of chronic pain is that is provides no biologic function. 
Acute pain is useful to alert the body to a noxious event and to stimulate the fight or flight 
response to stimuli. Alternatively, chronic pain has no purpose and evokes no response in the 
body. Emotional distress and behavioral dysfunction may result from chronic pain syndromes 
(Ballas, 2005).  Other psychosocial factors that should be considered as the child gets older are 
their feelings about their mental and physical changes during growth and the development of 
their peer relationships. Children with SCD typically lag behind growth and development curves 
by up to two years. They should be reassured that they will catch-up and will be an average size 
as an adult. Children have to learn how to manage unpredictable absences from school or social 
gatherings due to illness. They also need to understand the limitations to their physical activity 
and learn to avoid dehydration, extreme temperatures, and overexertion (Wethers, 2000a).  
3.2 PAIN MANAGEMENT IN THE EMERGENCY DEPARTMENT 
Sickle cell disease (SCD) is associated with vaso-occlusive pain crises that cause chronic pain, 
organ failure, significant morbidity, mortality and impaired quality of life. These pain crises 
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often require frequent visits to the emergency room and admissions to the hospital. It has been 
estimated that charges of $36 million per year is a result of hospital use in this population and 
that another $14.4 million per year is a result of emergency department (ED) use alone (Aisiku et 
al., 2007). Vaso-occlusive crises account for 79-91% of emergency room visits and 59-68% of 
all hospital admissions in sickle cell patients. Most admissions last on average from 8-11 days 
(Jacob, 2005 & 2008).  
Vascular occlusion is the hallmark of sickle cell disease. A severe, acute pain episode is 
defined as one that requires treatment with narcotics for four or more hours in a medical facility. 
If a patient experiences three or more of these acute pain crises he/she is classified as having 
severe SCD (Ballas, 2005). At initial presentation, about 50% of patients show objective signs of 
pain crisis; these include fever, leukocytosis, joint effusions, and tenderness. As the pain crisis 
develops, objective laboratory signs are evident in most patients; the percentage of dense red 
blood cells increases while there is a decrease in red blood cell deformability, many patients 
develop hyperhemolysis, decreased hemoglobin levels, and an increased reticulocyte count 
(Ballas, 2005).  
When considering how to manage pain, it should be kept in mind that prevention of pain 
is always better than treatment (Jacob & Mueller, 2008). There is some evidence that acute 
painful crises can lead to long-term health consequences, even when the vaso-occlusive episode 
appears to have been resolved.  In untreated pain, injured tissue can send sensory input to the 
spinal cord neuron causing any subsequent responses to be enhanced. If this severe pain goes 
untreated, it is possible that long-lasting changes in the nerve cells may occur that lead to the 
development of chronic pain (Jacob & Mueller, 2008).  In addition, when pain is severe and 
established, it is often more difficult to control.  Studies have found that persistent pain has an 
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underlying physiological mechanism that is different from the physiology of prolonged acute 
pain (Jacob & Mueller, 2008). It is therefore very important for patients with SCD to receive 
effective and aggressive treatment as soon as possible.  
The standard form of treatment for pain crises in SCD is by the use of narcotics such as 
morphine and hydromorphone (Givens, 2006); however effective pain management is complex 
and requires a thorough knowledge and understanding of the issues surrounding chronic pain 
management of an incurable disease. Some of these issues include understanding the 
pathophysiology of SCD, the pharmacology of the analgesics, and how the attitude of the 
physician may affect care and treatment (Ballas, 2005).     
Effective pain management in the treatment of sickle cell disease should be personalized 
for each patient in order to avoid making generalizations about patients and their response to 
analgesics. For example, a patient who has a lot of experience to opioids may experience less 
pain relief from the standard dose, while a patient who has little experience with opioids may 
experience over sedation (Ballas, 2005). Physicians treating these patients should have basic 
knowledge about their patients, including age, sex, diagnosis, complications, and previous pain 
management methods. Additionally, physicians should know information in order to assess the 
psychosocial and socioeconomic conditions of the patient; this may include knowing the 
patient’s education level, family structure, housing conditions, ethnicity, religion/beliefs, and 
perception of the severity of his/her disease (Ballas, 2005; Wilson et al., 2003). Sickle cell 
disease is complex and pain experiences may be affected by social, cultural, and psychological 
factors rather than only pathophysiologic factors. Besides the issues discussed above, pain 
management in SCD may be more effectively managed by following four steps: assessment, 
treatment, reassessment, and adjustment (Ballas, 2005).  
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3.2.1 Four steps for effective pain management 
Assessment is the most important factor in effective pain management. Since pain experiences 
are subjective, patient’s self-report is necessary in during evaluation (Ballas, 2005).  This self-
report should include descriptions of the intensity, quality, location, distribution, onset, duration, 
and factors that help in the relief of the pain or that aggravate the pain. Assessment should also 
include determining the presence of other complicating factors (for example, infection), family 
member’s reports, and vital signs, including: temperature, respiration rate, pulse, blood pressure, 
and pulse oximetry. Pain intensity may be measured by a variety of scales such as a numerical, 
visual, or verbal scale, or the Baker-Wong faces scale for children (Ballas, 2005). The same scale 
should be used routinely to allow the patient and healthcare provider to become familiar with the 
scale and what ratings mean for the particular patient. The goal of assessment is to establish a 
baseline level for which effective pain management will be compared to (Ballas, 2005).  
Following a baseline assessment, a treatment should be discussed that is personalized for 
the individual. Factors that should be considered are the choice of analgesic, the dose, and the 
route of administration. As treatment is progressing, the patient should be reassessed to 
determine how well the pain is being managed. Based on this reassessment, adjustments should 
be made to better manage the individual’s pain. This may include increasing the dose of 
analgesic to better control pain, decreasing the dose of analgesic as pain resolves, and identifying 
any adverse effects of the treatment or any complications from the disease. These steps should be 
repeated as necessary until pain has resolved (Ballas, 2005).  
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3.2.2 Methods and medications used in sickle cell pain management 
Pain that is mild to moderate in severity may be treated at home using a combination of 
nonpharmacolgic and analgesic options (Ballas, 2005).  Mild pain may be lessened by the use of 
non-pharmacologic methods and/or non-opioids. More severe pain may include the use of an 
opioid with or without an adjuvant. Severe, acute pain may be treated in a medical facility with 
the use of intravenous or intramuscular analgesics (Ballas, 2005). A combination of long- and 
short-acting opioids have been found to work best in managing both chronic sickle cell pain and 
frequent acute pain (Ballas, 2005). Day hospitals are an option in some cities with experts in 
SCD pain management available to evaluate patients promptly, without the delay commonly 
found in emergency departments (Ballas, 2005; Benjamin et al, 2000).  Day hospitals have been 
found to reduce the number of unnecessary admissions to the hospital (Benjamin et al, 2000; 
Jacob & Mueller, 2008).  
3.2.2.1 Non-pharmacologic management of pain 
Non-pharmacologic management of pain may include methods such as cutaneous 
stimulation, massage, relaxation, heat, cold, and vibration, distraction, music, guided imagery, 
self-hypnosis, self-motivation, acupuncture, and biofeedback (Ballas, 2005).  
3.2.2.2 Non-opioids 
Non-opioids that may be used for the management of pain in patients with SCD include 
acetaminophen, non-steroidal anti-inflammatory agents (NSAIDs), topical agents, tramadol, and 
corticosteroids (Ballas, 2005). Non-opioids have a ceiling effect where above certain doses there 
is no increased analgesic effect. Acetaminophen is an analgesic without anti-inflammatory 
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properties; high doses may cause liver damage. NSAIDs are analgesics that also have anti-
inflammatory properties; adverse effects include gastropathy, nephropathy, and hemostatic 
defects. NSAIDs should not be administered to individuals with renal disease or a history of 
peptic ulcer disease. Tramadol (Ultram) is an analgesic unrelated to opioids but with opioids and 
anti-depressant properties; it has been found to be effective in patients with mild to moderately 
severe sickle cell related pain (Ballas, 2005). 
3.2.2.3 Opioids 
Opioid agonists are commonly used in the management of pain in individuals with SCD 
(Ballas, 2005). They work by reducing or modifying the perception of pain by the central 
nervous system. They have fewer adverse effects than NSAIDs; however, their use in patients 
with SCD is associated with the spread of myths regarding addiction and drug-seeking behavior 
(Ballas, 2005).  Adverse effects include itching, nausea, vomiting, sedation, respiratory distress, 
and seizures. Opioids do not have a ceiling effect; therefore the only reason to limit 
administration of opioids is due to the adverse effects listed above. These medications can be 
given in a variety ways, including orally, intravenously, transdermally, subcutaneously, or 
intramuscularly, and also by a variety of methods, including continuous intravenous drip, patient 
controlled analgesia pump, or by injection (Ballas, 2005). 
3.2.2.4 Adjuvant Therapies 
Adjuvant therapies include antihistimines, antidepressants, benzodiazepines, and 
anticonvulsants. These medications work to increase and sustain the effects of opioids and lessen 
their side effects (Ballas, 2005). In addition, some also have mild analgesic properties. Adjuvants 
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should be administered carefully and closely monitored as they have their own side effects and 
may potentially worsen complications already present in patients with SCD (Ballas, 2005).  
3.2.2.5 Hydroxyurea 
Hydroxyurea is a cytotoxic medication that has been shown to reduce the number of pain 
crises in individuals with moderate to severe SCD by 50% (Ballas et al., 2006; Charache et al., 
2005; Stuart & Nagel, 2004; Wilson et al., 2003).  The mechanism of how hydroxyurea works to 
reduce pain crises is not entirely known, but some studies have shown that heme groups can 
oxidize hydroxyurea to produce nitric oxide (NO) free-radicals; these free-radicals mediate the 
activation of soluble guanylyl cyclase, which in turn increases γ-globin expression and HbF 
synthesis (Cokic et al., 2003). In addition, hydroxyurea may lower white blood cell, reticulocyte, 
and platelet counts, improve red blood cell hydration, increase NO production, and decrease 
RBC adhesiveness (Hankins et al., 2009).  Fetal hemoglobin inhibits sickling of the RBCs due to 
its lack of β-globin chains; it is composed of two α-globin and two γ-globin subunits. Levels of 
HbF sustained over 20% are associated with reduced clinical events in patients with SCD; while, 
decreased concentration of HbF has been recognized as a predictor of early mortality in patients. 
Clinical observations have found that increased HbF due to hydroxyurea has significantly 
reduced the frequency of pain episodes, as well as led to reductions in the frequency of acute 
chest syndrome and the number of transfusions required. The long-term effects of hydroxyurea 
are not currently known (Charache et al., 2005) and no evidence indicates that there is an 
increased risk for malignancies. Studies of the long-term effects are ongoing (Hankins et al., 
2009).  
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3.2.3 Improved pain management in the ED 
Despite the availability of national guidelines that address the ethical issues of pain management 
(published by the Joint Commission for the Accreditation of Healthcare Organizations (JCAHO) 
and the American Pain Society; Jacob et al., 2003; Todd et al., 2007; Yagood et al., 2000), 
patients with SCD often receive suboptimal pain control, especially during acute painful 
episodes (Jacob et al., 2003; Maxwell et al., 1999; Rupp & Delaney, 2004). This may be a result 
of physicians’ limited knowledge about SCD or a lack of training in chronic pain management 
(Aisiku et al., 2007). In addition, sickle cell patients may be stereotyped as being drug seekers or 
abusers by health care professionals who are not familiar with SCD (Aisiku et al., 2007; Jacob, et 
al., 2003; Maxwell et al., 1999). This mistrust may lead health care professionals to attempt to 
excessively control the patient’s pain management. Besides mistrust between the physician and 
the sickle cell patient, access to care may be limited by the patients’ socioeconomic status. The 
education and income levels of SCD patients are similar to that of other African-Americans, 
however, unemployment rates are higher and the personal income rates are lower for individuals 
with SCD (Aisiku et al., 2007).   
In cases where patients are rarely admitted to the hospital, it has been found that 
physicians may actually over-treat sickle cell pain (Maxwell et al., 1999), suggesting that 
physicians are not only concerned about addiction, but also about issues of trust, control, and 
patient involvement (Maxwell et al., 1999). This lack of patient involvement in pain management 
decision making may undermine self knowledge and self reliance, thus reducing the patients’ 
ability to management his/her pain independently; repeated cycles of control and neglect lead to 
mistrust of the healthcare professional and anxiety about receiving satisfactory pain 
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management. Previous studies have found that sickle cell patients experience under treatment of 
pain, lack of involvement in treatment decisions, and stigmatization (Maxwell et al., 1999).  
Patient dissatisfaction may affect compliance or the utilization of treatment and resources 
(Aisiku et al., 2007).  Satisfaction may be measured through the use of surveys that ask 
individuals to rate the overall care and treatment they received (Margaret et al., 2002). In 
addition, individuals may be asked to rate how respectfully they were treated. Ratings of respect 
may indicate professionalism of the health care provider and satisfaction with not only physical 
treatment, but psychosocial and emotional treatment (Margaret et al, 2002; Maxwell et al., 1999; 
Duff, 2004). Most recurrent acute pain episodes are managed in the ED (Aisiku et al., 2007), 
thus the ED is a good place to begin improving pain management for patients with SCD.  
Some studies have found that establishing early intervention and/or preventative 
protocols for treatment of pain may help to better control pain in patients with SCD (Jacob & 
Mueller, 2008). These interventions may include having protocols in place in an ED for 
aggressive early pain management and hydration. If pain is better controlled, chronic pain may 
be less likely to develop (Jacob & Mueller, 2008) and patients may feel more satisfied with their 
pain management.  
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 Figure 4: How hospital experiences may adversely influence individual pain management  
(Maxwell, et al., 1999) 
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4.0  MATERIALS AND METHODS 
4.1 SPECIFIC AIM I: RETROSPECTIVE DATA 
IRB approval was obtained for an exempt study (Appendix B). Data for this study were obtained 
from the Pediatric Health Information System (PHIS), an administrative database that contains 
the inpatient data from 40 not-for-profit, tertiary care pediatric hospitals in the United States. 
These hospitals are affiliated with the Child Health Corporation of America (CHCA; Shawnee 
Mission, KS), a business alliance of children’s hospitals. Data quality and reliability are assured 
through a joint effort between the CHCA and participating hospitals. The data warehouse 
function for the PHIS database is managed by Thomson Healthcare (Durham, NC). For the 
purposes of external benchmarking, participating hospitals provide discharge data including 
demographics, diagnoses, and procedures. Data are deidientified at the time of data submission, 
and data are subjected to a number of reliability and validity checks before being processed into 
data quality reports. Data are accepted into the database once classified errors occur less 
frequently than a criterion threshold. If a hospital’s quarterly data is unacceptable according to 
these limits, all of their quarterly data is rejected; however, this data can be resubmitted and 
reevaluated prior to inclusion in the database. For this study, data from four hospitals was 
included. This data was used, in aggregate, to compare various aspects of emergency department 
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visits and admissions of sickle cell patients with data from the Children’s Hospital of Pittsburgh 
(CHP).   
Individualized pain plans for each patient were put in place at Children’s Hospital of 
Pittsburgh in 2002-2003.  These include a personalized medication list for emergency visits and 
in-patient stays. PHIS data summaries for admissions, readmissions, average length of stay, 
discharges and days per patient, and CMI were provided, and were used to compare CHP to a 
selected group of hospitals. These hospitals were chosen due to their similar programs and 
patient populations. Data was specifically collected for admissions due to pain crisis and 
excluded patients with acute chest syndrome. Additionally, two medical record numbers were 
excluded from the CHP data because, based on experience with these patients, they were known 
to be outliers. The statistical program SPSS was used, with the help of Dr. Eleanor Feingold, to 
perform logistic binomial regression to determine whether there has been a significant change in 
admission rates since individualized pain plans for each sickle cell patient had been implemented 
in 2002 to the present between CHP and other hospitals.  
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4.2 SPECIFIC AIM II: CURRENT SATISFACTION LEVELS 
In addition to exempt IRB approval for evaluating retrospective data, expedited IRB approval 
was obtained to investigate current patient and parent satisfaction levels with pain management 
in the emergency department (Appendix A).  Permission to use a template for patient and parent 
satisfaction surveys was obtained from Dr. Jerris R. Hedges (Margaret et al., 2002).  These 
templates were modified to include some additional questions relevant to the Children’s Hospital 
of Pittsburgh and study aims (Appendices C-E).  
During the process of obtaining IRB approval, meetings were held with members of the 
ED staff to try to determine the best method of contacting and obtaining consent from patients. 
At that point, it was agreed that contact would be made when the patient came into the ED. 
When this method was put into place following IRB approval, it was found that is was difficult 
to catch many patients and to coordinate the PI meeting with the patients in the ED before being 
discharged. An IRB modification was submitted, and approved, at this point to allow contact to 
be made at any point following an ED visit by phone or in person; this included visiting the 
patient in sickle cell clinic, while they were in-patient, or while they were in the ED. A 
modification was also submitted and approved to waive signed consent in cases where surveys 
were conducted over the phone.  
The PI was notified when patients came into the ED each week. If the PI was not able to 
meet the patient in the ED, their name was added to a list that recorded the day the patient came 
into the ED. In addition, a query was run through the sickle cell database to find patients who 
had visited the ED in the past two years. Each week, the PI cross-checked the list of patients seen 
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in the ED with the list of patients coming in to sickle cell clinic and the list of patients in house 
provided by the administrative assistant.  The PI would then meet with these patients to describe 
the study, obtain consent, and administer the surveys.  If patients were not scheduled for a clinic 
visit in the near future, they were called, the study was described, and they were asked if they 
were interested in participating. Consent forms were then sent in the mail and the patient was 
encouraged to call if there were any questions or if they did not want their information used in 
the study.  
Data was analyzed using SPSS; descriptive statistics and p-values were obtained for each 
survey question for each age group. Values were also compared for children’s responses versus 
parent’s responses using independent T-tests.  
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5.0  RESULTS AND DATA ANALYSIS 
5.1 SPECIFIC AIM I: EVALUATING RETROSPECTIVE DATA 
Data from CHP and the Pediatric Health Information System (PHIS) were obtained from David 
Kaizmer, Systems Analyst III with CHP’s Quality Services. Data Summaries for admissions, 
readmissions, average length of stay, discharges and days per patient, and case mix index (CMI) 
were used to compare CHP to a selected group of hospitals. It was believed that admission rates, 
and possibly readmission rates, would be the most accurate predictor of patient care. This was 
assumed because length of stay, discharges per patient, and days per patient (Appendix G) have 
the potential to be biased to show a positive trend by unsatisfactory care. For example, a patient 
may be discharged before he/she is ready leading to a shorter length of stay and days per patient. 
These numbers may reflect well on the hospital, but not accurately gauge patient care and 
satisfaction. On the other hand, if admission rates are decreasing, it is likely a reflection on care 
and pain management that patients are receiving in the emergency department. Readmission 
rates were also looked at since low readmission rates may indicate that pain is well enough 
controlled that the patient does not need to return to the hospital.  
Data for admission rates is shown in Appendix G and Figure 5; data for readmission rates 
is shown in Appendix G and Figure 6. The table of information includes the proportions of 
admissions and the total number of patients seen. These proportions were used for statistical 
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analysis by binary logistic regression to determine a p-values and whether there was a trend seen 
over the years and between the hospitals.  
Table 1 summarizes the results that were found for admission rates. Binary logistic 
regression found significant differences at α=0.05 for admission rates between CHP and PHIS, 
as well as significant differences in admission rates over the years analyzed for both CHP and 
PHIS. Finally, there was a significant difference between the hospitals from 2002 to 2008, 
quarter three. Readmission rates were found to not show a significant trend (Table 5). However, 
rates were relatively low over the years for both hospitals, ranging from 3.1% to 8.0% at CHP 
and from 3.9% to 6.9% for the PHIS hospitals.  
 
 
Figure 5: Admission data for CHP and PHIS from 2002 to 2008, quarter 3 
 
 29 
Table 1: Admission rates comparison between CHP and PHIS over time 
  P-value Interpretation at α=0.05 
Hospital <0.05 Significant difference between CHP and PHIS 
Year: CHP <0.05 Significant difference over years 
Year: PHIS <0.05 Significant difference over years 
Interaction <0.05 Significant difference over years between hospitals 
 
 
Figure 6: Data of readmission rates as a graph 
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5.2 SPECIFIC AIM II: EVALUATING CURRENT SATISFACTION  
5.2.1 Demographics 
Three similar surveys were administered to patients and their parents, depending on their age 
(Appendix C-E). Basic demographics of the study population are shown in table 2. Raw data for 
all groups are shown in Appendix H.1.  
Table 2: Demographics of study participants 
Age Range Number Male Female
5-11 years 7 1 6 
12-17 years 15 3 12 
18+ years 14 5 9 
Parent 31 0 31 
Total 67 9 58 
 
There were more female participants in each category; this makes sense for the parent 
category as women more often tend to be the primary caregiver. However, the reason for more 
females than males in the other categories is unexplained.  
5.2.2 Data for Children Age 5 to 11 
For children ages 5-11, four of seven (57.1%) rated overall care and treatment as “very 
good” or better; qualitative descriptors were correlated to numbers 0 (poor) to 5 (extraordinary). 
None of the participants in this age group rated overall care and treatment as poor (Figure 7).  
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Figure 7: Overall Care and Treatment Ratings (Ages 5-11) 
 
The rest of the questions for this age group were based on the Baker-Wong Faces scale (figure 
8). This scale was chosen because the surveys obtained and modified from Margaret et al. (2002) 
used this scale. 
 
Figure 8: Baker-Wong faces scale 
There was a significant change in the pain scores before coming in to the ED and after 
leaving the ED (p=0.010; Appendix H.2). Only one patient reported having a level 4 pain on 
average each day; six experienced little (1) to no (0) pain. On average, patients were not scared 
about coming in to the ED and almost all the participants’ fear had resolved by the time they left. 
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5.2.3 Data for Children Age 12 and Up   
For children ages 12 and over, 20 of 29 (69.0%) rated overall care and treatment as “very 
good” or better. Only one of the participants in this age group rated overall care and treatment as 
poor; there were two who gave a rating of “fair” and six who gave a rating of “good” (Figure 9). 
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Figure 9: Overall Care and Treatment Ratings (Ages 12-21) 
 
Based on the faces scale, 93.1% of participants rated the niceness of the staff and doctors 
as a 2 or better. Eighteen patients rated their pain as 5 out of 5 on the faces scale before visiting 
the ED. After visiting the ED, only 2 patients reported having a 5 out of 5 pain. There was a 
significant decrease in pain scores compared before and after being seen in the ED (p<0.05; 
Appendix H.2). Nineteen of 29 participants (65.5%) experienced little to no pain (0 to 2) on 
average each day.  
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Sixty-nine percent of participants (20 out of 29) believed that information regarding their 
pain management was given in a manner “very good” or better. When asked to rate how well 
their pain was managed there was a range of scores given by participants; 51.7% chose a score of 
“very good” (3) or better (4, 5) (Figure 10).  
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Figure 10: Distribution of Pain Management Ratings (Ages 12-21) 
 
In terms of respectfulness of the doctors and staff who took care of the patients in the ED, 
89.7% of patients ages 12-21 gave ratings of “very good” or better (Figure 11).  
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Figure 11: Distribution of Child Respectfulness Ratings 
 
Reported wait times varied greatly; the range of time participants reported spending in 
the waiting room before being taken into an exam room was from zero to 1470 minutes (24 
hours, 30 minutes), with the mean wait time for a room being 70.74 minutes. The median and the 
mode were 10 minutes; when outliers over 90% were removed the mean wait time was 13.76 
minutes with a range of 0 to 150 minutes.  The range of time reported for the patient to be seen 
by a doctor or a nurse once he/she was in an exam room was from zero to 390 minutes (6 hours, 
30 minutes), with an mean wait time to be seen of 53.70 minutes. The median and the mode were 
20 minutes; when outliers over 90% were removed the mean wait time was 32.83 minutes with a 
range of 0 to 210 minutes.  The time that patients reported waiting to receive pain medication 
ranged from 5 to 270 minutes (4 hours, 30 minutes); the mean time to receive pain medication 
was 53.34 minutes (Appendix H.3). The median was 25 minutes and the mode was 10 minutes; 
 35 
when outliers over 90% were removed the mean wait time was 39.89 minutes with a range of 0 
to 180 minutes.   
Twenty-seven of 29 participants (93.1%) reported that they would return to the CHP 
emergency department. Only one participant (3.4%) reported that they would not return to the 
CHP emergency department, and only one participant reported that they were unsure whether 
they would return in the future.  Twenty-seven of 29 participants (93.1%) reported that they 
would recommend the ED to a friend. One participant (3.4%) reported that they would not 
recommend the ED to a friend, and one participant reported that they were unsure whether they 
would recommend this ED to a friend (Appendix H.1).   
5.2.4 Data for Parents  
The survey administered to parents of patients with SCD was similar to that given to patients 
ages 12 to 21.  Parents rated the overall treatment and care they received in the ED as “very 
good” or better in 24 out of 31 (77.4%) cases (Figure 12).  
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Figure 12: Overall Care and Treatment Ratings (Adults) 
  
Twenty out of 31 parents (64.5%) reported that their child had a pain level of 5 out of 5 on the 
faces scale before visiting the ED. After being seen in the ED, four parents reported that their 
child had a 5 out of 5 pain level. There was a significant change in pain scores that parents 
reported before and after their child was seen in the ED (p<0.05, Appendix H.2).  Twenty-seven 
out of 30 parents reported that their child experienced a level 2 or less amount of pain on a 
regular/daily basis.  
Twenty-two out of 31 parents (71.0%) reported that they were given information 
regarding their child’s pain management in a manner “very good” or better.  Twenty-two of 30 
parents (73.3%) believed that their child’s pain management was “very good” or better (Figure 
13). 
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Figure 13: Distribution of Pain Management Ratings (Adults) 
 
 The majority of parents (29 out of 31; 93.5%) reported that the doctors and staff who 
cared for their child were respectful.  
Like patients ages 12-21, the waiting rooms times estimated by parents varied greatly. 
The mean amount of time spent in the waiting room was reported to be 51.02 minutes, with a 
range from 0 to 660 minutes (11 hours). The median was 10 and the mode was 0 minutes; when 
outliers over 90% were removed the mean wait time was 13.16 minutes with a range of 0 to 60 
minutes. The mean amount of time reported being spent waiting in an exam room to be seen by a 
doctor or nurse was 14.52 minutes; however, the range was from 0 to 75 minutes (1 hour, 15 
minutes).  The median was 7 and the mode was 0 minutes; when outliers over 90% were 
removed the mean wait time was 10.82 minutes with a range of 0 to 37 minutes.  Finally, the 
mean amount of time spent waiting for pain medication was reported to be 43.63 minutes, with a 
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range from 0 to 360 minutes (6 hours).  The median was 20 and the mode was 60 minutes; when 
outliers over 90% were removed the mean wait time was 24.85 minutes with a range of 0 to 60 
minutes. (Appendix H.3).  
Ten parents reported that they had been to the ED 3 or more times in the last year. 
Thirteen parents reported that they had needed to bring their child to the ED 2 to 3 times in the 
last year; eight parents only had to bring their child to the ED once in the last year (Figure 14).  
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Figure 14: ER Visits Reported in the Past Year 
 
There was only one parent who reported that they would not recommend the CHP 
emergency department to a friend and only one parent who was unsure if they would recommend 
this ED. Only one parent reported that they would not return to the CHP emergency department 
in the future. All other parents reported that they would both recommend the Children’s Hospital 
of Pittsburgh’s ED and would return in the future.  (Appendix H.1) 
 39 
5.2.5 Qualitative Data 
A number of participants took the time to discuss and write comments about what they felt could 
be improved in their care and pain management. One patient, who rated overall care as “good,” 
stated that “one of the doctors [I] had didn’t seem like he really believed that [I] was in pain, and 
he didn’t follow [my] pain plan.” There were not any other similar comments, however, another 
patient alluded to doctors not reviewing her pain plan; her comment was that there “should be a 
record of all the medicines [I] take so [I] don’t have to say them every time a new doctor comes 
in.” While this patient rated overall care as “excellent,” she did indicate that it took four and a 
half hours to receive medication for her pain. A different patient wrote that “staff doesn’t seem to 
know as much about sickle cell or treatment of it than [I] expected;” she rated overall care as 
“good.” 
One of the most frequently written-in comments was regarding the time it took to be 
seen. A number of patients felt that the time it took to be seen was too long and expressed 
dissatisfaction due to the wait. One patient felt that “there are not enough nurses and doctors to 
tend to all the patients that come in to the ED;” this patient reported that it took six and a half 
hours to be seen by a doctor or nurse and rated overall satisfaction as “fair.” Another fairly 
common comment was that there should be more communication between the health care 
providers and the patients/parents. Patients and parents both commented about feeling frustrated 
at answering the same questions from different doctors while they were in severe pain and/or 
waiting for pain medication. One parent commented that, “[I] think most questions asked during 
time of trying to get medication started for patient could simply be asked if there are any changes 
instead of answering 25 questions while your child is in severe pain.” Additionally, a couple 
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patients mentioned that it was difficult to get physicians or staff to give them a direct answer or 
to get information about their treatment or that the provider was rude when questions were asked.  
A number of both patients and parents expressed satisfaction with care and included 
positive comments regarding their treatment and pain management. One parent commented that 
CHP was an excellent hospital where professional training is evident and that everyone was 
helpful and accommodating. Another parent noted that she has had great hospital ED 
experiences; both parents rated overall care and treatment as “extraordinary.” 
5.2.6 Overall Comparisons  
Children ages 5-11, 12-21 and parents gave similar ratings for overall treatment and care 
they received in the ED (p=0.49). There was also not a significant difference between the ratings 
children ages 12-21 and parents gave for how well information was given regarding their 
pain/pain management (p=0.47). Children (ages 12-21) and parents also gave similar ratings for 
how respectful the doctors and staff were (p=0.55). Additionally, children ages 5-11 and children 
ages 12-21 gave similar ratings when asked how nice the doctors and nurses were (p=0.22) 
(Appendix H.4). 
Parents and both age groups of children also gave similar pain ratings, before being seen 
in the ED (p=0.91), after leaving the ED (p=0.16), and on average each day (p=0.22). However, 
there was a significant difference between children ages 12-21 and parent ratings for how well 
pain was managed (p=0.044).  Parents gave a more positive rating for pain management (3.57; 
3=”Very Good” 4=”Excellent) than their children (2.78; 2=”Good”) (Appendix H.4).  
Parents and children ages 12-21 had similar estimates of time spent in the waiting room 
before being taken into an exam room and of the amount of time to receive pain medication 
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(p=0.922; p=0.103, respectively) . However, there was a significant difference in the estimate of 
how long it took to be seen by a doctor or a nurse (p=0.014). On mean without including outliers 
over 90%, children estimated that it took 32.83 minutes to be seen while parents estimated that it 
took 10.82 minutes to be seen (Appendix H.4). 
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6.0  DISCUSSION 
6.1 SPECIFIC AIM I: EVALUATING RETROSPECTIVE DATA 
Analysis of retrospective data from the Children’s Hospital of Pittsburgh (CHP) and the Pediatric 
Health Information System (PHIS) was performed to draw conclusions about whether patient 
care has improved in the past few years as knowledge about sickle cell disease has increased. At 
CHP, individualized pain plans were implemented in the emergency department (ED) in 2002-
2003. These pain plans contain the most recent record of medications each sickle cell patient has 
received on their last visit to the ED. It was believed that these pain plans would improve 
knowledge and understanding of sickle cell and help in the care and treatment of patients with 
SCD who present to the ED.  
Data from CHP and PHIS, including admission rates, were obtained through the Child 
Health Corporation of America (CHCA). Hospitals other than CHP were chosen due to their 
similar pediatric SCD programs and populations. Admission rates were picked as an indicator of 
patient care because it was believed that if admission rates decreased it is likely a reflection of 
how well patients were managed in the ED.  
Analysis of admission rates found that there was a significant difference in rates from 
2002 to the present for both CHP and PHIS; it was also found that there was a significant 
difference in admission rates between CHP and PHIS. The time of highest admission rates at 
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CHP was in 2002; over the years, the number of admissions has decreased significantly. This is 
an indication of improved treatment and care in the ED as fewer patients should be admitted if 
their pain is being well managed in a timely manner. Improved treatment and care may indicate 
increased knowledge about SCD by ED staff.  
Results of the retrospective data analysis also indicate that the use of individualized pain 
plans has been an important part of improving patient care.  Beginning in 2002, when these plans 
were first implemented, admission rates for CHP were almost 78%. By the end of the third 
quarter of 2008, six years after individualized pain plans were established, admission rates had 
dropped to about 52%.  
6.2 SPECIFIC AIM II: EVALUATING CURRENT SATISFACTION  
Patient and parent satisfaction surveys from Margaret, et al. (2002) were adapted to measure 
satisfaction with pain management in the Children’s Hospital of Pittsburgh emergency 
department. The mean rating of overall care and treatment given by children ages 5-21 and 
parents was a 3.30, where a rating of 3 correlated with “very good” and 4 with “excellent.” There 
was not a significant difference between the ratings that were given by parents and their children 
who were seen in the ED.  Additionally, parents and children rated the respectfulness of ED 
physicians and staff as a 3.98. These ratings indicate that parents and children who are treated in 
the CHP emergency department are satisfied with care and pain management.  
A significant difference was found in parent and children’s ratings of how well pain was 
managed. Parents gave a more positive rating than children did. This may be because the parents 
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are not the ones who were experiencing the pain and waiting for the treatment; they only saw 
that pain was usually resolved by the time they left the ED.  
It was also found that ratings of patient’s amounts of pain decreased significantly from 
before they came in to the ED compared to when they left the ED. This is likely to be a cause of 
many of the patient’s satisfaction levels with care. We only evaluated patients who came to the 
ED with pain and it is beneficial to know that the majority of patients experience resolution of 
their pain by the time they leave the ED. During discussions with the patients it was common for 
the patients who were admitted from the ED to still have a higher level of pain. It would be 
interesting for any future surveys to include a question on whether the patient was admitted in 
order to keep track of this information.  
Comments written in at the end of the surveys by patients and parents varied. A number 
of participants indicated that they were satisfied with overall care and felt like the Children’s 
Hospital ED had excellent service. However, there were some participants who wrote comments 
that the staff did not seem knowledgeable about SCD, or that the wait was too long, or that pain 
plans were not followed. Overall, individuals with negative feedback were less common than 
satisfied participants and most seemed to report that their negative experience was limited to one 
particular ED visit.  
Results from this study support previous work found in the literature. Patients with SCD 
have improved outcomes when treatment and care is personalized and when their pain 
management is designed specifically based on their past experiences. Additionally, if staff 
appeared to be unknowledgeable about SCD, patients were less satisfied with care.  
Based on surveys and talking with patients and parents about their satisfaction with pain 
management in the ED, it seemed like participants were often most concerned about how quickly 
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they were seen and how soon pain was brought under control.  In all age groups a majority of 
participants gave positive ratings regarding their overall treatment and care and seemed to be 
fairly satisfied with their pain management.  
6.3 FUTURE WORK 
Future work on this project should include collecting more data from patients, and their parents, 
who have recently been to the ED with pain. It may also be interesting and helpful to add a 
question on whether the patient was admitted to the hospital. Answers to the question may 
explain the cases where there was no, or very little, change in pain scores.  
If data is continuing to be collected, a quality improvement program should be designed 
while the last participants are being surveyed. This quality improvement program should 
consider how to best educate ED physicians and staff about sickle cell disease, its management, 
treatment, and how to care for patients with SCD. Information that may be included could be the 
pathophysiology of SCD, how SCD is inherited, the signs/symptoms of a vaso-occlusive pain 
crisis, triggers of a pain crisis, the clinical effectiveness guidelines for SCD pain management, or 
other complications of SCD.  Possible methods of how a quality improvement program might be 
implemented may include an in-service training breakfast/ lunch for staff and/or hanging posters 
about SCD in the staff areas of the ED.   
After the quality improvement program has been in place for a while, patient satisfaction 
should be reevaluated. This could be done by the administration of the same surveys, with any 
additional questions that may be deemed necessary. Scores from before and after the quality 
improvement plan was implemented may be compared to see if there has been a significant 
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change in patient and parent satisfaction with pain management. Additionally, it would be 
interesting to reanalyze the retrospective data again to see if admission rates decrease further.  
6.4 LIMITATIONS AND OTHER CONSIDERATIONS 
One limitation of this study is the small sample size. The study started off slow as it was difficult 
to contact patients under the original IRB submission. Restrictions had been placed on how long 
after their ED visit patients could be contacted, the method of contact, and the informed consent 
process. It took a while to work out the best way to resolve all of these issues. In the beginning, 
patients could only be contacted in the ED or if they had been admitted. If they had been 
admitted, it was difficult getting informed consent signed as many parents did not stay in the 
hospital with their children. In the ED, patients occasionally did not feel up to participating; 
when these patients were called at a later time, some still were not interested in talking, and 
given the original three day limitation of contact, surveys were unable to be obtained.  
The expedited IRB submission went through a few modifications in order to allow a 
broader method of participant contact. The final modification allowed patients to be contacted by 
phone, any time after being seen in the ED, and without written consent. This helped facilitate 
the contact of more patients over a longer time range. Before written consent was waived, it was 
difficult to sign-up any underage participants; the majority were over 18 years old and did not 
have a parent accompanying them. However, another limitation was run into when calling 
patients. Many phone numbers listed in the patient database were disconnected or wrong 
numbers. This made it difficult to reach the number of patients that was desired. In addition, if 
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families were reached, many parents seemed uncomfortable having their children answer survey 
questions over the phone.  
 Another limitation of this project was due to the extended time range added into the final 
modification. While a patient could be contacted any time after they had been to the ED, there 
was a limit of how well patients would remember their visit. A list of patients from who had 
been to the ED in the last two years was generated from the sickle cell database. Patients were 
removed from the list if they were younger than 5 years of age or if they had not come in due to 
pain. The remaining patients were called and given the option of participating in the survey. It 
was found that patients who had been in over a year ago often mentioned that they could not 
remember very well; some said that they would try to remember to the best of their ability while 
others declined to participate.  
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7.0  CONCLUSIONS 
Retrospective analysis of admissions data from CHP for patients with SCD coming to the ED 
due to vaso-occlusive pain showed that there has been a significant decrease in rates of 
admissions from 2002 to the present. As the hypothesis stated, it is believed that this is a 
reflection on better treatment and care of patients with SCD. The implementation of 
individualized pain plans for each patient with SCD has likely played a major role in increasing 
the quality of treatment and, thus, decreasing the rates of admission at CHP. During discussions 
with patients regarding their current satisfaction levels, a number mentioned that the pain plans 
have been helpful or would rate care lower if their pain plan was not used and followed. In 
addition, admission rates for CHP were significantly lower than those for PHIS hospitals from 
2002 to 2008 quarter 3, indicating that CHP is doing well with pain management for patients 
with SCD.  
 Overall, patients and their parents rated that their satisfaction with pain management in 
the ED was very good or excellent. Many patients experienced resolution of their pain by the 
time they left the ED. Some participants also mentioned how staff was improving in their 
knowledge and treatment of patients with SCD. A few mothers mentioned that as long as they 
called ahead to let the ED know that they were coming, they were taken back to a room 
immediately upon arrival and pain medications were administered. In general, it appeared that 
most individuals were satisfied with the care and treatment of their pain.  
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Now that a better method has been worked out for contacting patients it should be easier 
for any future work with this project to move forward at a quicker pace. In addition, any future 
work should be able to more easily enroll a larger number of participants. This will be helpful if 
and when a quality improvement program is implemented in the ED. Hopefully any follow-up 
measures of satisfaction will be more readily obtained. Once repeat survey results are collected, 
patient and parent satisfaction with pain management in the ED can be compared for before and 
after the implementation of a quality improvement program. If methods of improving satisfaction 
are found these may be developed for use in other hospitals that see patients with SCD or in 
ambulatory care.  
From a public health perspective, SCD is associated with pain crises that causes impaired 
quality of life and, in many cases, frequent trips to the ED and/or admissions to the hospital. If 
methods of increasing patient satisfaction with pain management and reducing admissions can be 
determined, these methods may be implemented in other hospitals or in ambulatory care. 
Increasing patient satisfaction by improved care, treatment, and pain management may help to 
improve the quality of life for patients with SCD.  
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APPENDIX A 
IRB APPROVAL LETTER-EXPEDITED STUDY 
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APPENDIX B 
IRB APPROVAL LETTER-EXEMPT STUDY 
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APPENDIX C 
SATISFACTION SURVEY: CHILD 5-11 YEARS 
CHP Pediatric ED Satisfaction Study 
Child Survey (5-11) 
 
Study ID#______________ 
1) How would you rate the overall treatment and care you received? 
Extraordinary Excellent Very Good Good      Fair         Poor 
 
2) How nice were the doctors and nurses to you? 
 
 
3) How much pain did you have before you came to the Emergency Department? 
 
 
4) How much pain did you have after you came to the Emergency Department? 
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 5) How much pain do you have every day? 
 
 
6) How scared were you before you saw the doctor? 
 
 
7) How scared are you now? 
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APPENDIX D 
SATISFACTION SURVEY: CHILD 12-21 YEARS 
CHP Pediatric ED Satisfaction Study 
Child Survey (12-21) 
 
Study ID#______________ 
1. How would you rate the overall treatment and care you received? 
Extraordinary      Excellent    Very Good      Good          Fair            Poor 
2. How nice were the staff and doctors to you? 
  
 
3. How much pain did you have before visiting the Emergency Department? 
  
 
4. How much pain did you have after visiting the Emergency Department? 
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5. How much pain do you have each day? 
               
6. How well was information given to you regarding your pain and pain management? 
  Extraordinary  Excellent Very Good Good      Fair         Poor 
 
7. Please estimate how much time you spent in the waiting room before being brought to the 
exam room? __________hours ___________minutes 
 
8. Please estimate how much time you spent in the exam room before being seen by the doctor? 
______________hours_______________ minutes 
 
9. How long did it take for you to receive medication for your pain? 
_____________hours ____________minutes 
 
10. How well was your pain managed? 
  Extraordinary  Excellent Very Good Good      Fair         Poor 
 
11. How respectful were the doctors and staff who took care of you? 
  Extraordinary  Excellent Very Good Good      Fair         Poor 
 
12. Would you recommend this emergency department to a friend? 
  Yes  No 
 
13. Would you return to this emergency department in the future? 
  Yes   No 
 
14. Any additional comments: 
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APPENDIX E 
SATISFACTION SURVEY: PARENT 
CHP Pediatric ED Satisfaction Study 
Child Survey (12-21) 
 
Study ID#______________ 
1) How would you rate the overall treatment and care you received? 
Extraordinary  Excellent Very Good Good      Fair         Poor 
2) How nervous were you about your child’s pain level?  
Extraordinarily      Extremely      Very  Moderately    Mildly           Not at all 
Nervous          Nervous      Nervous   Nervous            Nervous  Nervous   
 
3) How much pain did your child have before visiting the Emergency Department? 
 
4) How much pain did your child have after visiting the Emergency Department? 
 
5) How much pain is your child in on a regular/daily basis? 
 
6) How adequately were you informed regarding your child’s pain management? 
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Extraordinary  Excellent Very Good Good      Fair         Poor 
 
7) Please estimate how much time your child spent in the waiting room before being 
brought to the exam room? __________hours ___________minutes 
 
8) Please estimate how much time your child spent in the exam room before being seen by 
the doctor? ______________hours_______________ minutes 
 
9) How long did it take for your child to receive medication for his/her pain? 
_____________hours ____________ minutes 
 
10) How well do you feel your child’s pain was managed? 
Extraordinary  Excellent Very Good Good      Fair         Poor 
11) In the past year (not including your most recent visit) how many times have you brought 
one or more of your children to an emergency department for care? 
0-1 times 2-3 times more than 3 times 
12) Does your child have a regular primary care doctor/clinic? 
Yes   No 
13) How respectful were the doctors that took care of your child? 
Extraordinary  Excellent Very Good Good      Fair         Poor 
14) Would you recommend this emergency department to a friend? 
Yes  No 
15) Would you return to this emergency department in the future? 
Yes   No 
16)  Any additional comments: 
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APPENDIX F 
CHP CLINICAL EFFECTIVENESS GUIDELINES 
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APPENDIX G 
                            STATSTICAL ANALYSIS FOR SPECIFIC AIM I
Table 3: Admission rates for CHP compared to PHIS with proportions of patients admitted 
ADMISSION RATE         
 2002 2003 2004 2005 2006 2007 2008 
CHP 123 113 85 89 96 100 63 
 158 174 145 162 186 180 121 
 77.9% 64.9% 58.6% 54.9% 51.6% 55.6% 52.1% 
PHIS 1528 1397 1374 1389 1361 1312 903 
 2141 2114 2038 2060 2076 2071 1330 
 71.4% 66.1% 67.4% 67.4% 65.6% 63.4% 67.9% 
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Table 4: Data for readmission rates from CHP and PHIS from 2002 to 2008, quarter 3 
READMISSION RATE         
 2002  2003 2004 2005 2006 2007 2008 
CHP 9  4 6 3 3 8 2  
 123  113 85 89 96 100 63  
 7.3%  3.5% 7.1% 3.4% 3.1% 8.0% 3.2%  
PHIS 33  13 15 19 17 10 23  
 509  279 275 278 272 262 451  
 6.5%  4.7% 5.5% 6.8% 6.3% 3.8% 5.1%  
 
 
 
 
Table 5: Statistical analysis of readmission data 
 P-value Interpretation at a=0.05 
Hospital 0.942  No significant difference between CHP and PHIS 
Year: CHP 0.613  No significant difference over years 
Year: PHIS 0.364  No significant difference over years 
Interaction 0.941  No significant difference over years between hospitals 
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 Figure 15: Average length of stay data for SCD patients from 2002 to 2008, quarter 3 
 
 
 
 
Figure 16: Discharges per patient data for SCD patients from 2002 to 2008, quarter 3 
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 Figure 17: Days per patient data for SCD patients from 2002 to 2008, quarter 3 
 
 
 
 
Figure 11: Case mix index (CMI) data for SCD patients from 2002 to 2008, quarter 3 
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APPENDIX H 
STATISTICAL ANALYSIS FOR SPECIFIC AIM II 
H.1 RAW DATA 
Table 6: Data from ages 5-11 
Question number: vertical; answers and percentages: horizontal; questions from Appendix C 
Answer 0 (%) 1 (%) 2 (%) 3 (%) 4 (%) 5 (%) Mean
Question        
1 0 (0) 1 (14.3) 2 (28.6) 1 (14.3) 2 (28.6) 1 (14.3) 3
2 4 (57.1) 1 (14.3) 1 (14.3) 0 (0) 0 (0) 1 (14.3) 1.14
3 1 (14.3) 0 (0) 0 (0) 1(14.3) 0  (0) 5 (71.4) 4
4 3 (42.9) 1(14.3) 1 (14.3) 2 (28.6) 0 (0) 0 (0) 1.29
5 4 (57.1) 2 (28.6) 0 (0) 0 (0) 1 (14.3) 0 (0) 0.86
6 3 (42.9) 1 (14.3) 2 (28.6) 0 (0) 1 (14.3) 0 (0) 1.29
7 6 (85.7) 0 (0) 1 (14.3) 0 (0) 0 (0) 0 (0) 0.29
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Table 7: Data from ages 12-21 
Question number: vertical; answers and percentages: horizontal; questions from Appendix D 
A 0 (%) 1 (%) 2 (%) 3 (%) 4 (%) 5 (%) Mean
Q        
1 1 (3.4) 2 (6.9) 6 (20.7) 7 (24.1) 5 (17.2) 8 (27.6) 3.28
2 22 (75.9) 1 (3.4) 4 (13.8) 2 (6.9) 0 (0) 0 (0) 0.52
3 1 (3.4) 2 (6.9) 0 (0) 1 (3.4) 6 (20.7) 18 (62.1) 4.22
4 3 (10.3) 4 (13.8) 6 (20.7) 4 (13.8) 8 (27.6) 2 (6.9) 2.59
5 10 (34.5) 5 (17.2) 3 (10.3) 8 (27.6) 1 (3.4) 0 (0) 1.48
6 1 (3.4) 2 (6.9) 6 (20.7) 7 (24.1) 9 (31.0) 4 (13.8) 3.14
7 N/A N/A N/A N/A N/A N/A 70.74
8 N/A N/A N/A N/A N/A N/A 53.70
9 N/A N/A N/A N/A N/A N/A 53.34
10 2 (6.9) 4 (13.8) 7 (24.1) 4 (13.8) 9 (31.0) 2 (6.9) 2.78
11 0 (0) 1 (3.4) 2 (6.9) 5 (17.2) 10 (34.5) 11 (37.9) 3.97
12 0 (0) 27 (93.1) 1 (3.4) N/A N/A N/A 1.05
13 0 (0) 27 (93.1) 1 (3.4) N/A N/A N/A 1.05
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Table 8: Data from parents 
Question number: vertical; answers and percentages: horizontal; questions from Appendix C 
A 0 (%) 1(%) 2(%) 3(%) 4(%) 5(%) Mean
Q       
1 1 (3.2) 2 (6.5) 4 (12.8) 5 (16.1) 8 (25.8) 11 (35.5) 3.61
2 4 (12.8) 4 (12.8)  2 (6.5) 9 (29.0) 4 (12.8) 7 (22.6) 2.89
3 2 (6.5) 0 (0) 1 (3.2) 2 (6.5) 6 (19.4) 20 (64.5) 4.26
4 7 (22.6) 8 (25.8) 3 (9.7) 1 (3.2) 6 (19.4) 4 (12.8) 2.12
5 13 (41.9) 8 (25.8) 6 (19.4) 3 (9.7) 0 (0) 0 (0) 0.97
6 2 (6.5) 3 (9.7) 4 (12.8) 5 (16.1) 5 (16.1) 12 (38.7) 3.42
7 N/A N/A N/A N/A N/A N/A 51.02
8 N/A N/A N/A N/A N/A N/A 14.52
9 N/A N/A N/A N/A N/A N/A 43.63
10 0 (0) 4 (12.8) 4 (12.8) 5 (16.1) 5 (16.1) 12 (38.7) 3.38
11 8 (25.8) 13 (41.9) 10 (32.3) N/A N/A N/A 1.06
12 0 (0) 30 (100) N/A N/A N/A N/A 1.03
13 0 (0) 1 (3.2) 1 (3.2) 5 (16.1) 10 (32.3) 14 (45.2) 4.13
14 1 (3.2) 29 (93.5) 1 (3.2) N/A N/A N/A 1
15 1 (3.2) 30 (96.8) N/A N/A N/A N/A 0.97
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H.2 COMPARING BEFORE AND AFTER ED PAIN LEVELS 
Table 9: Pain Level Comparisons-Children 5-11 
   
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 
    F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
    Lower Upper Lower Upper Lower Upper Lower Upper Lower
outcome Equal 
variances 
assumed 
.270 .613 3.042 12 .010 2.714 .892 .770 4.658 
 
Table 10: Pain Level Comparisons-Children 12-21 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Outcome Equal 
variances 
assumed 
2.217 .142 4.365 56 .000 1.6379 .3752 .8863 2.3896
 
Table 11: Pain Level Comparisons-Adult 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Outcome Equal 
variances 
assumed 
6.234 .015 5.501 58 .000 2.241 .407 1.425 3.056
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H.3 DESCRIPTIVE STATISTICS FOR WAIT TIMES 
Table 12: Ages 12-21 Waiting Room Times 
With outliers 
 N Valid 29
Missing 0
Mean 70.74
Std. Error of Mean 50.690
Median 10.00
Mode 10
Std. Deviation 272.973
Variance 74514.083
Range 1470
Minimum 0
Maximum 1470
Percentiles 90 150.00
 
 
Without outliers 
N Valid 27
Missing 0
Mean 13.76
Std. Error of Mean 5.522
Median 5.00
Mode 10
Std. Deviation 28.695
Variance 823.411
Range 150
Minimum 0
Maximum 150
Percentiles 90 31.40
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Table 13: Ages 12-21 Exam Room Wait Times 
With outliers 
N Valid 28
Missing 1
Mean 53.70
Std. Error of Mean 16.905
Median 20.00
Mode 20
Std. Deviation 89.453
Variance 8001.766
Range 390
Minimum 0
Maximum 390
Percentiles 90 215.00
 
 
Without outliers 
N Valid 26
Missing 0
Mean 32.83
Std. Error of Mean 8.688
Median 20.00
Mode 20
Std. Deviation 44.300
Variance 1962.499
Range 210
Minimum 0
Maximum 210
Percentiles 90 86.50
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Table 14: Ages 12-21 Wait Times for Pain Medication 
With outliers 
N Valid 29
Missing 0
Mean 53.34
Std. Error of Mean 12.247
Median 25.00
Mode 10
Std. Deviation 65.953
Variance 4349.805
Range 265
Minimum 5
Maximum 270
Percentiles 90 180.00
 
 
Without outliers 
N Valid 27
Missing 0
Mean 39.89
Std. Error of Mean 8.308
Median 25.00
Mode 10
Std. Deviation 43.172
Variance 1863.795
Range 175
Minimum 5
Maximum 180
Percentiles 90 122.00
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Table 15: Parent Waiting Room Times 
Without outliers 
 N Valid 31
Missing 0
Mean 51.0161
Std. Error of Mean 26.61155
Median 10.0000
Mode .00
Std. Deviation 148.16683
Variance 21953.408
Range 660.00
Minimum .00
Maximum 660.00
Percentiles 90 60.0000
 
 
Without outliers 
 N Valid 29
Missing 0
Mean 13.1552
Std. Error of Mean 2.94982
Median 10.0000
Mode .00
Std. Deviation 15.88525
Variance 252.341
Range 60.00
Minimum .00
Maximum 60.00
Percentiles 90 37.0000
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Table 16: Parent Exam Room Wait Times 
Without outliers 
 N Valid 30
Missing 0
Mean 14.10
Std. Error of Mean 3.171
Median 7.00
Mode 0
Std. Deviation 17.367
Variance 301.610
Range 75
Minimum 0
Maximum 75
Percentiles 90 37.00
 
 
Without outliers 
 N Valid 28
Missing 0
Mean 10.82
Std. Error of Mean 2.237
Median 6.00
Mode 0
Std. Deviation 11.835
Variance 140.078
Range 37
Minimum 0
Maximum 37
Percentiles 90 35.20
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Table 17: Parent Wait Times for Pain Medication 
Without outliers 
 N Valid 27
Missing 0
Mean 24.85
Std. Error of Mean 4.288
Median 20.00
Mode 60
Std. Deviation 22.283
Variance 496.516
Range 60
Minimum 0
Maximum 60
Percentiles 90 60.00
 
 
Without outliers   
N Valid 27
Missing 0
Mean 24.85
Std. Error of Mean 4.288
Median 20.00
Mode 60
Std. Deviation 22.283
Variance 496.516
Range 60
Minimum 0
Maximum 60
Percentiles 90 60.00
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H.4 OVERALL COMPARISONS 
Table 18: Comparison of Overall Treatment Scores 
Group 0: Adults; Group 1: Children 12-21; Group 2: Children 5-11 
 Outcome  
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 2.971 2 1.486 .725 .488 
Within Groups 131.148 64 2.049     
Total 134.119 66      
 
 
 
Table 19: Comparison of Information Given 
Group 0: Adults; Group 1: Children 12-21 
  
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Outcome Equal 
variances 
assumed 
3.224 .078 .730 58 .468 .281 .385 -.490 1.053 
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Table 20: Comparisons of Respectfulness Ratings 
Group 0: Adults; Group 1: Children 12-21 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Outcome Equal 
variances 
assumed 
.016 .900 .600 58 .551 .164 .272 -.382 .709
 
 
Table 21: Comparison of "Niceness" Ratings 
Group 1: Children 12-21; Group 2: Children 5-11 
     
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Outcome Equal 
variances 
assumed 
3.455 .072 -1.249 34 .220 -.626 .501 -1.644 .392 
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Table 22: Comparison of Pre-ED Pain Levels 
Group 1: Children 12-21; Group 2: Children 5-11 
Outcome 
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups .383 2 .192 .095 .910 
Within Groups 129.729 64 2.027   
Total 130.112 66    
 
Table 23: Comparison of Post-ED Pain Levels 
Group 1: Children 12-21; Group 2: Children 5-11 
Outcome 
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 10.305 2 5.153 1.900 .158 
Within Groups 170.805 63 2.711   
Total 181.110 65    
 
Table 24: Comparison of Mean Daily Pain Levels 
Group 1: Children 12-21; Group 2: Children 5-11 
Outcome  
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 4.753 2 2.376 1.535 .223 
Within Groups 97.565 63 1.549     
Total 102.318 65      
 
Table 25: Comparison of Pain Management 
Group 0: Adults; Group 1: Children 12-21 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Outcome Equal 
variances 
assumed 
.060 .808 2.074 57 .043 .791 .381 .027 1.554
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Table 26: Comparison of Waiting Room Times 
Group 0: Adults; Group 1: Children 12-21 
     
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Wating Equal 
variances 
assumed 
.352 .556 .098 54 .922 .604 6.141 -11.708 12.916
 
 
 
Table 27: Comparison of Exam Room Waits 
Group 0: Adults; Group 1: Children 12-21 
     
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Wating Equal 
variances 
assumed 
8.644 .005 2.541 53 .014 21.689 8.535 4.570 38.808
 
 
 
Table 28: Comparison of Pain Meds Wait 
Group 0: Adults; Group 1: Children 12-21 
     
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Upper Lower 
Wating Equal 
variances 
assumed 
4.005 .050 1.657 53 .103 15.210 9.180 -3.202 33.623
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